## university of Alberta Research Identifies Potential New Treatment target for Multiple Sclerosis
Newly published research led by a team at the University of Alberta has uncovered a potential new therapeutic target for multiple sclerosis (MS). The study, published in *Nature Communications*, details how brain immune cells, called microglia, behave during myelin repair and identifies breakdowns in this process that contribute to the disease.
### Understanding Multiple sclerosis and Remyelination
Multiple sclerosis is a chronic autoimmune disease affecting the central nervous system – the brain and spinal cord. In MS, the protective covering of nerve fibers, known as myelin, is damaged or destroyed. This damage disrupts communication between the brain and the rest of the body, leading to a wide range of symptoms. Approximately 90,000 Canadians live with MS .A key goal in MS treatment is to promote *remyelination* – the repair of the myelin sheath. Currently, there are no approved medications specifically designed to enhance remyelination, representing a critically important unmet medical need.
### microglia and the Remyelination Process
“There are currently no medications to improve remyelination,a major unmet need,” says Jason Plemel,principal investigator of the study and a Canada Research Chair in Glial Neuroimmunology at the University of Alberta .
The research team used advanced single-cell analysis in mice to map the different states microglia undergo during prosperous remyelination. microglia are resident immune cells in the brain and play a crucial role in both damaging and repairing nervous tissue. The study revealed a specific sequence of changes in microglial behavior that are essential for effective myelin repair.
### Identifying Impairments in Older Animals and Relevance to MS
The researchers found that in older animals – were remyelination is naturally less efficient, mirroring the situation in MS – the microglial sequence was disrupted. Specifically, the microglia either failed to transition between states properly, were delayed in their response, or didn’t “switch off” after completing their repair function.
“This is the first map of the microglial states needed for successful remyelination,” explains Plemel. “By defining these states, we now have clear therapeutic targets that can be used to guide new treatments.”
### Building on Previous Research
This work extends Plemel’s previous investigations into the role of microglia in neurological diseases. His earlier research explored how microglia contribute to brain damage in conditions like MS and Alzheimer’s disease, and also their response to nerve damage from spinal cord injuries .
### Future Directions
This research provides a foundational understanding of the complex role of microglia in remyelination. By pinpointing specific microglial states crucial for repair, the team has opened avenues for developing targeted therapies to promote myelin regeneration in individuals with MS. Further research will focus on translating these findings into effective treatments and exploring the potential for personalized medicine approaches based on an individual’s microglial profile.